

ICMJE DISCLOSURE FORM

Date: 5/17/2022

Your Name: __ Kainat Saleem

Manuscript Title: __ The Role of Systemic Therapy in Melanoma Brain Metastases

Manuscript number (if known): __

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	

Please summarize the above conflict of interest in the following box:

None.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 5/17/2022

Your Name: Diwakar Davar

Manuscript Title: The Role of Systemic Therapy in Melanoma Brain Metastases

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Melanoma Research Foundation	
		Jack Buncher Foundation	
		Gateway Foundation for Cancer Research	
		R01 CA257265-02	
		P50 CA254865-01	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	Arcus	
		Checkmate Pharmaceuticals	
		CellSight Technologies	
		Immunocore	
		Merck	
		Tesaro/GSK	
3	Royalties or licenses	None	

4	Consulting fees	Checkmate Pharmaceuticals	
		Finch	
		Shionogi	
		Vedanta Biosciences	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Med Learning Group	
		Clinical Options	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	US Patent 63/124,231	"Compositions and Methods for Treating Cancer", Dec 11, 2020
		US Patent 63/208,719	"Compositions and Methods For Determining Responsiveness to Immune Checkpoint Inhibitors (ICI), Increasing Effectiveness of ICI and Treating Cancer", June 9, 2021
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	

Please summarize the above conflict of interest in the following box:

DD receives support from Melanoma Research Foundation, Jack Buncher Foundation, Gateway Foundation for Cancer Research, R01 CA257265-02, and P50 CA254865-01; grants from Arcus, Checkmate Pharmaceuticals, CellSight Technologies, Immunocore, Merck, and Tesaro/GSK; consulting fees from Checkmate Pharmaceuticals, Finch, Shionogi, and Vedanta Biosciences; and payment or honoraria from Med Learning Group and Clinical Options. DD has US Patent 63/124,231, for "Compositions and Methods for Treating Cancer", Dec 11, 2020; and US Patent 63/208,719, for "Compositions and Methods For Determining Responsiveness to Immune Checkpoint Inhibitors (ICI), Increasing Effectiveness of ICI and Treating Cancer", June 9, 2021.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.